Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 915953, 11 pages
http://dx.doi.org/10.1155/2013/915953
Research Article
Artemisia iwayomogi Extract Attenuates High-Fat Diet-Induced
Obesity by Decreasing the Expression of Genes Associated with
Adipogenesis inMice
Yeji Choi,1 Yasuko Yanagawa,1 Sungun Kim,2 Wan KyunnWhang,2 and Taesun Park1
1 Department of Food and Nutrition, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Republic of Korea
2 College of Pharmacy, Chung-Ang University, 221 Heuksuk-Dong, dongjak-gu, Seoul 156-756, Republic of Korea
Correspondence should be addressed to Taesun Park; tspark@yonsei.ac.kr
Received 17 October 2012; Accepted 20 December 2012
Academic Editor: Ravirajsinh N. Jadeja
Copyright Â© 2013 Yeji Choi et al.î¢is is an open access article distributed under theCreative CommonsAttribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
î¢e objective of the present study was to determine whether Artemisia iwayomogi (AI) extract reduces visceral fat accumulation
and obesity-related biomarkers in mice fed a high-fat diet (HFD), and if so, whether these eï¬€ects are exerted by modulation of
the expression of genes associated with adipogenesis and inï¿½ammation. AI extract supplementation for 11 weeks signiï¿½cantly
prevented HFD-induced increments in body weight, visceral adiposity, adipocyte hypertrophy, and plasma levels of lipids and
leptin. Additionally, AI extract supplementation resulted in downregulation of adipogenic transcription factors (PPARğ›¾ğ›¾2 and
C/EBPğ›¼ğ›¼) and their target genes (CD36, aP2, and FAS) in epididymal adipose tissue compared to the HFD alone. î¢e AI extract
eï¬€ectively reversed the HFD-induced elevations in plasma glucose and insulin levels and the homeostasis model assessment of
insulin resistance index. Furthermore, the extract signiï¿½cantly decreased gene expression of proinï¿½ammatory cytokines (TNFğ›¼ğ›¼,
MCP1, IL-6, IFNğ›¼ğ›¼, and INFğ›½ğ›½) in epididymal adipose tissue and reduced plasma levels of TNFğ›¼ğ›¼ and MCP1 as compared to HFD
alone. In conclusion, these results suggest that AI extract may prevent HFD-induced obesity and metabolic disorders, probably by
downregulating the expression of genes related to adipogenesis and inï¿½ammation in visceral adipose tissue.
1. Introduction
Adipogenesis is the process by which mesenchymal pre-
cursor cells diï¬€erentiate into adipocytes [1]. Although its
presence is necessary in many ways, excess adipose tissue
is associated with serious health problems such as obesity,
cardiovascular disease, and type 2 diabetes [2, 3]. Presently,
CCAAT/enhancer binding protein ğ›¼ğ›¼ (C/EBPğ›¼ğ›¼) and peroxi-
some proliferator-activated receptor ğ›¾ğ›¾2 (PPARğ›¾ğ›¾2) are consid-
ered the 2 primary transcription factors that mediate adipo-
genesis. It has been reported that inactivation of PPARğ›¾ğ›¾2 and
C/EBPğ›¼ğ›¼ in adipose tissue protects against obesity in rodent
models [4â€“6].î¢us, potential therapeutic agents that have the
ability to inhibit adipogenesis could have a profound impact
as a strategy for preventing obesity and related metabolic
disorders.
Adipose tissue not only serves as an organ for energy
storage, but also as an endocrine organ by releasing vari-
ous inï¿½ammatory cytokines such as tumor necrosis factor
ğ›¼ğ›¼ (TNFğ›¼ğ›¼) and interleukin- (IL-)6 [7â€“9]. Proinï¿½ammatory
molecules produced by adipose tissue have been implicated
as active participants in the development of inï¿½ammation
and the increased risk of obesity-related insulin resistance
[9â€“11]. Increased production of monocyte chemoattractant
protein 1 (MCP1), interferon (IFN) ğ›¼ğ›¼, IFNğ›½ğ›½, TNFğ›¼ğ›¼, and
IL-6 in adipose tissue has been reported in animal models
of obesity [8â€“10, 12]. î¢erefore, therapeutic agents that
attenuate proinï¿½ammatory cytokines may prove useful in the
medical management of obesity-induced inï¿½ammation.
Artemisia iwayomogi (AI), a member of Compositae,
is a perennial herb easily found throughout Korea. It has
been used as a traditional medicine and is known to have
2 Evidence-Based Complementary and Alternative Medicine
antiallergic, antiapoptotic, and antioxidant eï¬€ects [13â€“16].
It has been reported that a carbohydrate fraction from
AI suppresses spontaneous or 2,3,7,8-tetrachlorodibenzo-p-
dioxin-induced apoptotic death of mouse thymocytes [14,
15]. Artemisia iwayomogi extract displays scavenging activity
of peroxynitrite, a potent cytotoxic oxidant formed by the
reaction between nitric oxide and superoxide radicals [16].
In addition, to our knowledge, few studies have described
the beneï¿½cial eï¬€ects of AI in high-fat diet-(HFD-) fed obese
rodents. One study reported that oral administration of AI
extract signiï¿½cantly reduced serum lipid levels in HFD-fed
rats [17]. A recent study by Cho et al. reported that oral
administration of AI extract to HFD-fed mice provoked
upregulation of PPARğ›½ğ›½ and its target genes involved in fatty
acid oxidation in the skeletal muscle [18]. To date, however,
no study has assessed the protective eï¬€ects of AI extract
on adipose tissue dysfunction in diet-induced obese animal
models. î¢erefore, the present study aimed to investigate
whether AI extract could reduce visceral fat accumulation
and improve obesity-related biomarkers in HFD-fed mice,
and if so, whether these eï¬€ects were exerted by modulation
of the expression of genes associated with adipogenesis and
inï¿½ammation.
2. Material andMethods
2.1. Preparation of AI Extract. Artemisia iwayomogi was
collected fromKorean standard products inMarch 2008, and
was identiï¿½ed by Professor Wan Kyun Whang of the Phar-
maceutical Botany Laboratory at Chung-Ang University in
Seoul, Republic of Korea, where a voucher specimen has been
deposited. Dried AI (500 g) was washed in water, oven dried
at 40âˆ˜C, mechanically fragmented, and then was powdered
in an electric mill. î¢e powder was extracted 5 times with
ethanol (powder : solvent = 1 : 5) at room temperature. Aî‚er
ï¿½ltration, the extraction was vacuum concentrated to yield
6.25% ethanol extract (31.3 g), which was stored at âˆ’4âˆ˜C until
use.
2.2. HPLC Analysis. Chromatography was performed using
a Water HPLC system (Water Corporation, Milford, MA,
USA) with an autosampler. HPLC separation was conducted
using a Kromasil C18 column (4.6mm Ã— 250mm, 5-ğœ‡ğœ‡m
inner diameter) at 30âˆ˜C with a ï¿½ow rate of 1.0mL/min
using a gradient mobile phase composed of water (A) and
acetonitrile (B). î¢e mobile phase comprised an 80 : 20
mixture of component A to B as the initial condition of
the chromatographic run, and component B was increased
to 80% in a linear gradient in 30min. î¢e sample injection
volume was 10 ğœ‡ğœ‡L. î¢e identities of the compounds in the
AI extract were conï¿½rmed by 1H-NMR, 13C-NMR, and MS,
with individual purities of not less than 95%.
2.3. Animals and Experimental Protocol. Male C57BL/6J
mice (5 weeks old) were purchased from Orient Bio (Gyeo-
nggi-do, Republic of Korea) and were maintained in 12 h
light/dark with ad libitum access to food and water. Aî‚er a
1-week acclimatization period, the mice were divided into
3 groups (ğ‘›ğ‘› ğ‘› 1ğ‘› per group): normal diet (ND), HFD, and
0.5% AI extract-supplemented diet (AED). î¢e ND was a
puriï¿½ed diet based on the AIN-76 rodent diet composition.
î¢e HFD was identical to the ND, but to which 200 g
fat/kg (170 g lard plus 30 g corn oil) and 1% cholesterol
had been added. î¢e AED was identical to the HFD but
contained 0.5% (w/w) AI extract. î¢e mice were fed the
experimental diets for 11 weeks. Diet consumption was
monitored daily, and body weight was monitored weekly.
At the end of the feeding period, mice were anesthetized
with diethyl ether aî‚er an overnight fasting for 16 h, and
their blood samples were collected in EDTA-coated tubes.
Plasma samples were isolated by centrifugation at 4000Ã—g for
20min and stored at âˆ’80âˆ˜C for subsequent analysis. Adipose
and liver tissues were collected, washed with phosphate-
buï¬€ered saline, and frozen at âˆ’80âˆ˜C. All animal experiments
were performed in accordance with the Korean Food and
Drug Administration guidelines. î¢e Institutional Animal
Care and Use Committee of the Yonsei Laboratory Animal
Research Center reviewed and approved the protocols.
2.4. Biochemical Analysis. Plasma concentrations of triglyc-
erides (TGs), free fatty acids (FFAs), glucose, total cholesterol,
and HDL cholesterol were measured using commercial kits
(Bio-Clinical System, Gyeonggi-do, Republic of Korea). LDL
+ VLDL cholesterol levels were calculated by subtracting
HDL cholesterol from total cholesterol. Plasma insulin levels
were analyzed using a mouse insulin ELISA kit (ALPCO
Diagnostics, Windham, NH, USA). î¢e homeostasis model
assessment of insulin resistance (HOMA-IR) index was
calculated as fasting plasma glucose concentration (mmol/L)
multiplied by fasting insulin level (pmol/L) divided by 22.5.
Plasma levels for leptin, TNFğ›¼ğ›¼, and MCP1 were measured
using a mouse ELISA kit (ID Labs, Cambridge, MA, USA).
Hepatic lipids were extracted as described by Folch et al.
[19], using a chloroform-methanol mixture (2 : 1 v/v), and
the dried lipid residues were dissolved in 2mL ethanol.
Concentrations of cholesterol, triglyceride, and free fatty
acids in the hepatic lipid extracts were measured using the
same enzymatic kits that were used for the plasma analysis.
2.5. Histological Analysis. White adipose tissues (WATs)were
ï¿½xed in neutral buï¬€ered formalin, embedded in paraï¿½n,
and sectioned into 5 ğœ‡ğœ‡m sections onto slides. For histology,
sectionswere stainedwith hematoxylin and eosin (H&E).î¢e
sectional areas of WAT were analyzed to quantify the size of
the adipocytes.
2.6. RNA Extraction and Semiquantitative RT-PCR. Total
RNA was isolated from the epididymal adipose tissue of
each mouse with TRIzol (Invitrogen, Carlsbad, CA, USA)
according to the manufacturerâ€™s instruction. Isolated RNA
was quantiï¿½ed using a spectrophotometer, and cDNA was
synthesized using reverse transcriptase (Invitrogen). î¢e
PCR was programmed as follows: 10min at 94âˆ˜C; 30â€“33
cycles at 94âˆ˜C for 30 s, 55âˆ˜C for 30 s; 72âˆ˜C for 1min;
10min incubation at 72âˆ˜C. Four microliters of each PCR
reaction weremixed with 1 ğœ‡ğœ‡L of 6-fold concentrated loading
buï¬€er and loaded onto 2% agarose gel containing ethidium
bromide. î¢e GenBank accession numbers of the relevant
Evidence-Based Complementary and Alternative Medicine 3
Tï¡ï¢ï¬ï¥ 1: Primer sequences and RT-PCR conditions.
Gene description Primers Sequences (5â€²â†’ 3â€²) ğ‘‡ğ‘‡ğ‘šğ‘š (âˆ˜C) Size (bp)
Peroxisome proliferator-activated receptor ğ›¾ğ›¾2 (PPARğ›¾ğ›¾2) F TTCGGAATCAGCTCTGTGGA 55 148
R CCATTGGGTCAGCTCTTGTG
CCAAT/enhancer binding protein ğ›¼ğ›¼ (C/EBPğ›¼ğ›¼) F AAGGCCAAGAAGTCGGTGGA 55 189
R CCATAGTGGAAGCCTGATGC
Adipocyte protein 2 (aP2) F ACATGAAAGTGGGAGTG 55 128
R AAGTACTCTCTGACCGGATG
Cluster of diï¬€erentiation 36 (CD36) F ATGACGTGGCAAAGAACAGC 55 160
R GAAGGCTCAAAGATGCCTCC
Fatty acid synthase (FAS) F TTGCCCGAGTCAGAGAACC 55 171
R CGTCCACAATAGCTTCATAGC
Monocyte chemoattractant protein 1 (MCP1) F CCAGCAAGATGATCCCAATG 55 450
R CTTCTTGGGGTCAGCACAGA
Interferon ğ›¼ğ›¼ (IFNğ›¼ğ›¼) F ATGGCTAG(G/A)CTCTGTGCTTTCCT 60.2 500
R GGGCTCTCCAGA(T/C)TTCTGCTCTG
Interferon ğ›½ğ›½ (IFNğ›½ğ›½) F TGGAGCAGCTGAATGGAAAG 55 122
R GAGCATCTCTTGGATGGCAA
Tumor necrosis factor ğ›¼ğ›¼ (TNFğ›¼ğ›¼) F TGTCTCAGCCTCTTCTCATT 55 156
R AGATGATCTGAGTGTGAGGG
Intereukin 6 (IL-6) F TTGCCTTCTTGGGACTGATG 55 162
R CCACGATTTCCCAGAGAACA
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) F AGAACATCATCCCTGCATCC 60 321
R TCCACCACCCTGTTGCTGTA
templates and forward (F) and reverse (R) primer sequences
are shown in Table 1. î¢e measured mRNA levels were nor-
malized to the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA levels.
2.7. Statistical Analysis. î¢e data on body weight gain,
plasma biochemistries, and adipocyte diameter are presented
as the mean Â± SEM of 10 mice. RT-PCR results are presented
as themeanÂ± SEMof at least 3 separate experiments. All anal-
yses were performed using SPSS (version 12.0). Data were
analyzed by 1-way ANOVA, followed by Duncanâ€™s multiple
range tests. ğ‘ƒğ‘ƒ values <0.05 were considered signiï¿½cant.
3. Results
3.1. Chromatographic Analysis of Artemisia iwayomogi
Extract. î¢e HPLC chromatogram revealed that scopolin
(AI-I, 1.21% w/w), acetophenone glycoside (AI-II, 0.26%
w/w), and scopoletin (AI-III, 0.38% w/w) were the major
components among the organic molecules of the AI extract,
which exhibited maximum absorbance at 280 nm (Figure 1
and Table 2).
3.2. Body and Visceral Fat Pad Weights. AED-fed mice
exhibited signiï¿½cantly decreased body weight gain (âˆ’52%)
and ï¿½nal body weight (âˆ’19%) compared to HFD-fed mice
without their food intake being aï¬€ected (Figures 2(a)â€“2(c)).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A
U
0 2 4 6 10 12 14 16 18 20 22 24 26 28 30
Minutes
AI-I
AI-II
AI-III
8
Fï©ï§ïµï²ï¥ 1: HPLC chromatogram of theArtemisia iwayomogi extract.
î¢e peaks were assigned based on the isolation of each compound.
AI-I: scopolin; AI-II: acetophenone glycoside; AI-III: scopoletin
(see Table 2).
î¢e food eï¿½ciency ratio (FER) was signiï¿½cantly lower in
AED-fed mice (âˆ’54%) compared to HFD-fed mice (Figure
2(d)). î¢e AI extract supplementation led to a signiï¿½cant
decrease in total visceral fat pad weight (âˆ’64%) compared
to the HFD alone. î¢is was attributable to weight decreases
in the epididymal (âˆ’54%), retroperitoneal (âˆ’58%), perirenal
(âˆ’83%), and mesenteric (âˆ’69%) adipose depots (ğ‘ƒğ‘ƒ < ğ‘ƒğ‘ƒğ‘ƒğ‘ƒ
for all depots; Figures 2(e) and 2(f)). î¢e H&E sections of
epididymal adipose tissues revealed that adipocyte diameter
(âˆ’20%) was signiï¿½cantly decreased in AED-fed mice than in
HFD-fed mice (Figure 2(g)).
4 Evidence-Based Complementary and Alternative Medicine
Tï¡ï¢ï¬ï¥ 2: Proï¿½le of compounds in the Artemisia iwayomogi extract.
Compound IUPAC name Structure Contents (%)
(1) Scopolin
6-methoxy-2-oxo-2H-chromen-
7-yl
ğ›½ğ›½-D-glucopyranoside
H
H
H
H
H
O
O
O
O O
OH
HO
OH
OH
1.21 Â± 0.07
(2) Acetophenone
glycoside
2,4-dihydroxy-6-
methoxyacetophenone
4-O-ğ›½ğ›½-D-glucopyranoside
O
O
O
H H
HH
H
OH
OH
HO
OH
OH
H3CO
0.26 Â± 0.01
(3) Scopoletin 7-hydroxy-6-methoxychromen-2-one
O
O OHO
0.38 Â± 0.04
3.3. Plasma Biochemistries. Plasma concentrations of TG
(âˆ’47%), FFA (âˆ’47%), total cholesterol (âˆ’47%), HDL choles-
terol (âˆ’34%), and LDL + VLDL cholesterol (âˆ’59%) were all
signiï¿½cantly lower in AED-fed mice than in HFD-fed mice
(ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘ƒğ‘ƒğ‘ƒğ‘ƒ, Figures 3(a)â€“3(e)). AED-fedmice had signiï¿½cantly
lower plasma concentrations of leptin (âˆ’71%) than HFD-
fed mice (Figure 3(f)). Likewise, the AI extract signiï¿½cantly
attenuated the elevation in plasma concentrations of glucose
(âˆ’42%) and insulin (âˆ’21%) in HFD-fed mice (Figures 3(g)
and 3(h)). î¢e HOMA-IR calculations revealed that the AI
extract signiï¿½cantly decreased the HOMA-IR index (âˆ’49%)
compared to HFD alone (Figure 3(i)). AED-fed mice had
signiï¿½cantly lower plasma concentrations of MCP1 (âˆ’60%)
and TNFğ›¼ğ›¼ (âˆ’46%) than HFD-fed mice (Figures 3(j) and
3(k)).
3.4. Hepatic Lipid Accumulation. AED-fed mice had sig-
niï¿½cantly lower liver weight (âˆ’30%) than in HFD-fed
mice (Figure 4(a)). Hepatic triglyceride (âˆ’66%), cholesterol
(âˆ’51%), and free fatty acid (âˆ’75%) concentrations were
markedly lower in AED-fed mice than in HFD-fed mice
(Figures 4(b)â€“4(d)).
3.5. Expression of Genes Related to Adipogenesis. Examina-
tion of adipogenic gene expression in epididymal adipose
tissue showed that mRNA levels of PPARğ›¾ğ›¾2 (âˆ’44%) and
C/EBPğ›¼ğ›¼ (âˆ’18%), regulators of adipogenic molecules, were
signiï¿½cantly lower in AED-fed mice than in HFD-fed mice.
î¢e expressions of PPARğ›¾ğ›¾2 target genes, including cluster
of diï¬€erentiation 36 (CD36) (âˆ’29%), adipocyte fatty acid
binding protein (aP2) (âˆ’35%), and fatty acid synthase (FAS)
(âˆ’58%), were all signiï¿½cantly decreased in AED-fed mice
than in HFD-fed mice (Figure 5).
3.ï¿½. Expression of Genes Related to ï¿½nï¿½ammation. Based on
the active roles of proinï¿½ammatory cytokines in obesity-
related inï¿½ammation, we examined the eï¬€ect of AI extract on
proinï¿½ammatory cytokine expressions in epididymal adipose
tissue. Compared to HFD-fed mice, the epididymal adipose
tissue in AED-fed mice contained signiï¿½cantly decreased
mRNA levels of several proinï¿½ammatory cytokines, includ-
ing TNFğ›¼ğ›¼ (âˆ’41%), IL-6 (âˆ’28%), MCP1 (âˆ’32%), IFNğ›¼ğ›¼
(âˆ’41%), and IFNğ›½ğ›½ (âˆ’38%) (Figure 6).
4. Discussion
î¢is feeding study was designed to assess whether AI extract
supplementation for 11 weeks could improve diet-induced
obesity and obesity-related biomarkers in mice. Based on
a preliminary study involving diï¬€erent AI extract dosages
(0.5%, 1%, and 2%), we determined that 0.5% AI extract
was the minimal eï¬€ective dose for preventing weight gain
Evidence-Based Complementary and Alternative Medicine 5
0
2
4
6
8
10
12
14
16
0 7 14 21 28 35 42 48 56 63 70 77
Days
ND
HFD
AED
Body weight gain (g/11 wks)
a
a
a
a a
a
a
a
a
a a
bb
bb
bb
b
b b
b
b
b
b
b
b
b
b
b
b
b bb
(a)
a
b
b
Final body weight (g)
20
25
30
35
40
45
ND HFD AED
(b)
a
b
b
2
2.5
3
3.5
ND HFD AED
Food intake (g/day)
(c)
a
b b
0.02
0.04
0.06
0.08
ND HFD AED
FER
(d)
a
a
a
a
a
b b
b b b b
b b
b
b
ND
HFD
AED
Visceral fatpad weights (g)
0
0.5
1
1.5
2
2.5
3
3.5
Epididymal Retroperitoneal Perirenal Mesenteric Total
(e)
ND HFD AED
Epididymal
Retroperitoneal
Perirenal
Mesenteric
(f)
ND
ND
HFD
HFD
AED
AED
40
60
80
100
120
Adipocyte diameter
(g)
Fï©ï§ïµï²ï¥ 2: Eï¬€ects of Artemisia iwayomogi extract supplementation on body weight gain, food eï¬ƒciency ratio, and visceral fat pad weights
of mice fed with high-fat diet. Mice were fed ï¿½D, HFD, or AED for 11 weeks. Changes in (a) body weight gain, (b) ï¿½nal body weight, (c)
food intake, (d) FER, (e), (f) visceral fat pad weights, (g) representative pictures of H&E-stained fat cells frommice epididymal adipose tissue
(Ã—100), and densitometric analysis of adipocyte diameter in epididymal tissue. Data representmeanÂ± SEM, ğ‘›ğ‘› ğ‘› ğ‘›ğ‘›. Meanswithout a common
letter diï¬€er, ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘›ğ‘ƒğ‘›ğ‘ƒ. FER = (body weight gain for experimental period (g))/(food intake for experimental period (g)).
in HFD-fed mice (data not shown). Hence, the 0.5% AI
extract was considered for this study. In the present study,
the AI extract signiï¿½cantly decreased not only body weight
gain, but also visceral adiposity and adipocyte hypertrophy
in HFD-fed mice. Since visceral adiposity is positively cor-
related to plasma leptin concentration, the circulating leptin
level is an ideal indicator for assessing obesity in both
experimental animals and humans [20, 21]. In this context,
6 Evidence-Based Complementary and Alternative Medicine
0.5
1
1.5
ND HFD AED
Triglyceride (mmol/L)
a
b
c
(a)
400
600
800
1000
ND HFD AED
ab
a
b
(b)
1
2
3
4
5
ND
b
a
b
HFD AED
Total cholesterol (mmol/L)
(c)
0
0.3
0.6
0.9
1.2
1.5
HDL cholesterol (mmol/L)
ND HFD AED
b
b
a
(d)
1
2
3
LDL + VLDL cholesterol (mmol/L)
ND HFD AED
b
b
a
(e)
0
7
14
21
28
35
Leptin (ng/mL)
ND HFD AED
b
b
a
(f)
1
4
7
10
Glucose (mmol/L)
ND HFD AED
c
a
b
(g)
0.2
0.4
0.6
0.8 Insulin (pg/ml)
ND HFD AED
c
a
b
(h)
0
0.2
0.4
0.6
0.8
1
1.2
HOMA-IR
ND HFD AED
c
a
b
(i)
10
30
50
70
90
MCP1 (pg/ml)
ND HFD AED
c
a
b
(j)
20
40
60
80
100
ND
c
a
b
HFD AED
5/'à¦© 	QHN-

(k)
Fï©ï§ïµï²ï¥ 3: Eï¬€ects of Artemisia iwayomogi eï¿½tract supplementation on plasma levels of lipids, leptin, glucose, insulin, and proinï¿½ammatory
cytokines in mice fed with high-fat diet. (a) Triglyceride, (b) free fatty acid, (c) total cholesterol, (d) HDL cholesterol, (e) LDL + VLDL
cholesterol, (f) leptin, (g) glucose, (h) insulin, (i) HOMA-IR, (j) MCP1, and (k) TNFğ›¼ğ›¼. Bars represent mean Â± SEM, ğ‘›ğ‘› ğ‘› ğ‘›ğ‘›. Means without
a common letter diï¬€er, ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘›ğ‘ƒğ‘›ğ‘ƒ.
Evidence-Based Complementary and Alternative Medicine 7
0.5
1
1.5
2
Liver weight (g)
ND HFD AED
b
a
b
(a)
ND HFD AED
b b
a
0
10
20
30
40
50
5SJHMZDFSJEF 	à¦´NPMH MJWFS

(b)
ND HFD AED
c
a
b
20
30
40
50
60
70
$IPMFTUFSPM 	à¦´NPMH MJWFS

(c)
ND HFD AED
a
b
b
0
2
4
6
8
10
'SFF GBUUZ BDJE 	à¦´&RH MJWFS

(d)
Fï©ï§ïµï²ï¥ 4: Eï¬€ects of Artemisia iwayomogi extract supplementation on liver weights and hepatic lipid levels in mice fed with high-fat diet. (a)
Liver weights and concentrations of hepatic (b) triglyceride, (c) cholesterol, and (d) free fatty acids. Means without a common letter diï¬€er,
ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘ƒğ‘ƒğ‘ƒğ‘ƒ.
CD36
aP2
FAS
GAPDH
ND HFD AED
PPARí›¾2
$&#1à¦©
(a)
CD36 aP2 FAS
ND
HFD
AED
0
b b
b
b
b
b bb
b
c
a
a
a a
a
1
2
3
R
el
at
iv
e 
ge
n
e 
ex
p
re
ss
io
n
PPARí›¾2 $&#1à¦©
(b)
Fï©ï§ïµï²ï¥ 5: Eï¬€ects of Artemisia iwayomogi extract supplementation on genes regulating adipogenesis in epididymal adipose tissue of mice fed
with high-fat diet. (a) Representative example of semiquantitative RT-PCR revealing the expression levels of adipogenic genes in epididymal
adipose tissue and their quantitative analysis. î¢e data represent relative density normalized to GAPDH. Data represent the results of 3
independent experiments. Bars represent mean Â± SEM. Means without a common letter diï¬€er, ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘ƒğ‘ƒğ‘ƒğ‘ƒ.
8 Evidence-Based Complementary and Alternative Medicine
ND HFD AED
IL-6
MCP1
GAPDH
5/'à¦©
*/'à¦©
*/'à¦ª
(a)
ND
HFD
AED
0
b
a a a
a
a
b
b b
b
bbc c c1
2
3
4
5
6
R
el
at
iv
e 
ge
n
e 
ex
p
re
ss
io
n
IL-6 MCP15/'à¦© */'à¦© */'à¦ª
(b)
Fï©ï§ïµï²ï¥ 6: Eï¬€ects of Artemisia iwayomogi extract supplementation on expression of proinï¿½ammatory cytokine genes in epididymal
adipose tissue of mice fed with high-fat diet. (a) Representative example of semi-quantitative RT-PCR revealing the expression levels
of proinï¿½ammatory cytokines in epididymal adipose tissue and their quantitative analysis. Data represent the results of 3 independent
experiments. Bars represent mean Â± SEM. Means without a common letter diï¬€er, ğ‘ƒğ‘ƒ ğ‘ƒ ğ‘ƒğ‘ƒğ‘ƒğ‘ƒ.
the lower plasma leptin level recorded in the AED-fed mice
may be attributable to the prevention of visceral adipocyte
hypertrophy.
As there was no signiï¿½cant diï¬€erence in food con-
sumption between HFD- and AED-fed mice, the beneï¿½cial
eï¬€ects of the AI extract on body weight gain and visceral
fat accumulation evidently did not depend on decreased
energy intake. î¢us, we hypothesized that the AI extract
reduced HFD-induced body weight gain and visceral fat
accumulation by mediating the inhibition of adipogenesis.
î¢at the expression of PPARğ›¾ğ›¾2 and C/EBPğ›¼ğ›¼ in WAT is
upregulated in HFD-induced obese animals is well known [4,
22]. Increased PPARğ›¾ğ›¾2 and C/EBPğ›¼ğ›¼ function cooperatively
to transactivate adipocyte genes, including FAS, CD36, and
aP2 [23â€“26]. FAS catalyzes the reactions for the synthesis of
long-chain fatty acids [27], whereas CD36 and aP2 facilitate
the uptake of long-chain fatty acids in adipocytes [23, 28],
thereby increasing adipocyte size and fat accumulation. In the
current study, the AI extract signiï¿½cantly reversed the HFD-
induced upregulation of adipogenic transcription factors
(PPARğ›¾ğ›¾2 and C/EBPğ›¼ğ›¼) and their target genes (FAS, CD36,
and aP2) in the epididymal adipose tissue of mice. î¢ese
decreased expressions of adipogenic genes by the AI extract
may have contributed to the lower visceral adiposity and
body weight gain. In addition, the AI extract signiï¿½cantly
decreased plasma FFA levels in HFD-fed mice. As increased
plasma concentrations of FFA form a vicious relationship
with PPARğ›¾ğ›¾2 activation in diet-induced obese animals [29,
30], the decreased FFA level in the AED-fed mice might also
be considered associated with PPARğ›¾ğ›¾2 inactivation.
Increased adipose tissue accumulation in obese individ-
uals correlates with the overproduction of proinï¿½ammatory
cytokines that play crucial roles in the development of
obesity-induced inï¿½ammation [8, 11]. In obese animals,
excess adipose tissue increases the expression and secretion
of TNFğ›¼ğ›¼, a prototypical inï¿½ammatory cytokine [4, 9, 12]. In
turn, increased TNFğ›¼ğ›¼ activates adipocytes, thereby further
enhancing the expression of various proinï¿½ammatory genes
such as MCP1, IL-6, IFNğ›¼ğ›¼, and IFNğ›½ğ›½ [31, 32]. IL-6 induces
a hepatic acute-phase reaction with upregulated acute-phase
proteins, including C-reactive protein and ï¿½brinogen [33,
34], whereas MCP1 contributes to macrophage inï¿½ltration
into adipose tissue, which leads to chronic inï¿½ammation
[35]. IFNğ›¼ğ›¼/ğ›½ğ›½ directly stimulates IFNğ›¾ğ›¾ production, a regulator
of innate immune response, in T cells [36]. Our results
suggested that the decrease in visceral adiposity by the AI
extract might have contributed, in part, to the decreased
expression of proinï¿½ammatory cytokines (TNFğ›¼ğ›¼, MCP1, IL-
6, IFNğ›¼ğ›¼, and IFNğ›½ğ›½) and reduced plasma levels of TNFğ›¼ğ›¼
andMCP1. Consequently, the decreased gene expression and
secretion of proinï¿½ammatory cytokines in the AED-fed mice
may have contributed to the prevention of obesity-induced
inï¿½ammation.
Several studies have demonstrated that cytokines play
crucial roles in the development of insulin resistance [35, 37â€“
39]. In diet-induced obese animals, increased plasma levels
of TNFğ›¼ğ›¼, IL-6, MCP1, and leptin have been shown to impair
the ability of insulin to activate signal transduction and
stimulate glucose uptake into skeletal muscle and adipose
tissue [35, 37â€“41].î¢us, in the present study, improvement of
insulin resistance by the AI extract might be associated with
decreased gene expression and/or production of cytokines
such as TNFğ›¼ğ›¼, IL-6, MCP1, and leptin.
Separation and determination of chemical constituents
are generally recommended for standardization and quality
control of herbal products and herb-related investigations
[42]. Several studies have demonstrated that AI contains
ï¿½avonoids such as genkwanin and ï¿½aceosidin [43], essential
oils, including eugenol and 1,8-cineole [44], and coumarin
compounds such as scopoletin and scopolin [43, 45]. In
addition, scopoletin has been used as a standard compound
for the veriï¿½cation and identiï¿½cation of AI [46, 47]. In
the present study, we isolated not only scopoletin, but also
scopolin and acetophenone glycoside from the AI extract
(Figure 1 and Table 2). Of these, scopolin (1.21%) was
the most abundant, followed by scopoletin (0.38%) and
acetophenone glycoside (0.26%). In addition, the scopolin
content of the AI extract was higher in our study than that
Evidence-Based Complementary and Alternative Medicine 9
observed by Kim et al. (0.49% w/w) and Ding et al. (0.2%
w/w) [43, 45]. î¢is diï¬€erence may be due to the diï¬€ering
extraction and isolation methods as well as diï¬€erences in
plant material [43, 45]. Previous studies have shown that
coumarin compounds from Fraxinus rhynchophylla [48],
Angelica gigas [49], and Ionidium suï¬€ruticosum [50] inhibit
adipocyte diï¬€erentiation in 3T3-L1 cells and/or reduce body
weight gain and plasma lipid levels in mice fed a high-fat
diet. î¢us, the antiobesity activity of AI extract observed
in the present study may be attributable to the presence of
high amounts of coumarin compounds in the plant. Further
studies are needed to determine the major active compounds
in AI extract that are responsible for decreased visceral
adiposity and other obesity-related biomarkers.
In summary, the present study showed that AI extract
reduced visceral fat accumulation in HFD-fed mice and
improved the risk factors related to the metabolic syndrome,
such as inï¿½ammation and insulin resistance. î¢e evidence
obtained in this study suggests that the beneï¿½cial eï¬€ects of
AI extract may be due to, at least in part, downregulation of
the genes related to adipogenesis and inï¿½ammation in the
visceral adipose tissue of mice. î¢erefore, dietary supple-
mentation with this extract, if validated in human studies,
may provide an adjunctive therapy for the prevention and/or
treatment of obesity and metabolic syndrome.
Abbreviations
AI: Artemisia iwayomogi
AED: Artemisia iwayomogi extract-supplemented
diet
aP2: Adipocyte protein 2
C/EBPğ›¼ğ›¼: CCAAT/enhancer binding protein ğ›¼ğ›¼
CD36: Cluster of diï¬€erentiation 36
FAS: Fatty acid synthase
FFA: Free fatty acids
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
HFD: High-fat diet
HOMA-IR: Homeostasis model assessment of insulin
resistance
IFNğ›¼ğ›¼: Interferon ğ›¼ğ›¼
IFNğ›½ğ›½: Interferon ğ›½ğ›½
IFNğ›¾ğ›¾: Interferon ğ›¾ğ›¾
IL-6: Interleukin-6
MCP1: Monocyte chemoattractant protein 1
ND: Normal diet
PPARğ›¾ğ›¾2: Peroxisome proliferator-activated receptor ğ›¾ğ›¾2
TG: Triglyceride
TNFğ›¼ğ›¼: Tumor necrosis factor ğ›¼ğ›¼.
Acknowledgments
î¢is research was supported by the Korea Health 21 R&D
Project (Project no. A110532), Ministry of Health and Wel-
fare, Republic of Korea, and by Industrialization Support
Program for Biotechnology of Agriculture and Forestry
(Project no. 810002031SB110), Ministry for Food, Agricul-
ture, Forestry, and Fisheries, Republic of Korea.
References
[1] S. M. Rangwala and M. A. Lazar, â€œTranscriptional control of
adipogenesis,â€Annual Review of Nutrition, vol. 20, pp. 535â€“559,
2000.
[2] H.M. Lakka, D. E. Laaksonen, T. A. Lakka et al., â€œî¢emetabolic
syndrome and total and cardiovascular disease mortality in
middle-agedmen,â€ Journal of the AmericanMedical Association,
vol. 288, no. 21, pp. 2709â€“2716, 2002.
[3] M. Perley and D. M. Kipnis, â€œPlasma insulin responses to
glucose and tolbutamide of normal weight and obese diabetic
and nondiabetic subjects,â€Diabetes, vol. 15, no. 12, pp. 867â€“874,
1966.
[4] S. Kim, Y. Jin, Y. Choi, and T. Park, â€œResveratrol exerts anti-
obesity eï¬€ects via mechanisms involving down-regulation of
adipogenic and inï¿½ammatory processes in mice,â€ Biochemical
Pharmacology, vol. 81, no. 11, pp. 1343â€“1351, 2011.
[5] T. Yamauchi, H. Waki, J. Kamon et al., â€œInhibition of RXR and
PPARğ›¾ğ›¾ ameliorates diet-induced obesity and type 2 diabetes,â€
Journal of Clinical Investigation, vol. 108, no. 7, pp. 1001â€“1013,
2001.
[6] N. D. Wang, M. J. Finegold, A. Bradley et al., â€œImpaired energy
homeostasis in C/EBPğ›¼ğ›¼ knockout mice,â€ Science, vol. 269, no.
5227, pp. 1108â€“1112, 1995.
[7] E. Bertin, P. Nguyen, M. Guenounou, V. Durlach, G. Potron,
and M. Leutenegger, â€œPlasma levels of tumor necrosis factor-
alpha (TNF-ğ›¼ğ›¼) are essentially dependent on visceral fat amount
in type 2 diabetic patients,â€ Diabetes and Metabolism, vol. 26,
no. 3, pp. 178â€“182, 2000.
[8] J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W.
Bahouth, â€œComparison of the release of adipokines by adipose
tissue, adipose tissue matrix, and adipocytes from visceral and
subcutaneous abdominal adipose tissues of obese humans,â€
Endocrinology, vol. 145, no. 5, pp. 2273â€“2282, 2004.
[9] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman,
â€œAdipose expression of tumor necrosis factor-ğ›¼ğ›¼: direct role in
obesity-linked insulin resistance,â€ Science, vol. 259, no. 5091, pp.
87â€“91, 1993.
[10] H. Xu, G. T. Barnes, ï¿½. Yang et al., â€œChronic inï¿½ammation in fat
plays a crucial role in the development of obesity-related insulin
resistance,â€ Journal of Clinical Investigation, vol. 112, no. 12, pp.
1821â€“1830, 2003.
[11] M. Maachi, L. PiÃ©roni, E. Bruckert et al., â€œSystemic low-grade
inï¿½ammation is related to both circulating and adipose tissue
TNFğ›¼ğ›¼, leptin and IL-6 levels in obese women,â€ International
Journal of Obesity, vol. 28, no. 8, pp. 993â€“997, 2004.
[12] S. J. Kim, Y. Choi, and Y. H. Choi, â€œObesity activates toll-like
receptor-mediated proinï¿½ammatory signaling cascades in the
adipose tissue of mice,â€î‚»e Journal of Nutritional Biochemistry,
vol. 23, no. 2, pp. 113â€“122, 2012.
[13] S. H. Kim, C. H. Choi, S. Y. Kim, J. S. Eun, and T. Y. Shin, â€œAnti-
allergic eï¬€ects of Artemisia iwayomogi on mast cell-mediated
allergymodel,â€ Experimental Biology andMedicine, vol. 230, no.
1, pp. 82â€“88, 2005.
[14] H. J. Ji, H. K. Yeo, N. H. Lee et al., â€œA carbohydrate fraction,
AIP1, from Artemisia iwayomogi down-regulates Fas gene
expression and suppresses apoptotic death of the thymocytes
induced by 2,3,7,8-tectrachlorodibenzo-p-dioxin,â€ Biotechnol-
ogy Letters, vol. 27, no. 4, pp. 253â€“257, 2005.
[15] J. S. Hwang, H. J. Ji, K. A. Koo et al., â€œAIP1, a water-
soluble fraction from Artemisia iwayomogi, suppresses thymo-
cyte apoptosis in vitro and down-regulates the expression of fas
10 Evidence-Based Complementary and Alternative Medicine
gene,â€ Biological and Pharmaceutical Bulletin, vol. 28, no. 5, pp.
921â€“924, 2005.
[16] Y. Ding, J. A. Kim, S. Y. Yang, W. K. Kim, S. H. Lee, and H. D.
Jang, â€œAntioxidative sesquiterpenes fromArtemisia iwayomogi,â€
Notes, vol. 32, no. 9, p. 3493, 2011.
[17] N. Sang-Myung, H. Seung-Shi, O. Duk-Hwan, K. Il-Jun, and L.
Sang-Young, â€œEï¬€ects of Artemisia iwayomogi kitamura ethanol
extract on lowering serum and liver lipids in rats,â€ Journal of the
Korean Society of Food Science and Nutrition, vol. 27, no. 2, pp.
338â€“343, 1998.
[18] S. Y. Cho, H. W. Jeong, J. H. Sohn, D. B. Seo, and W. G. Kim,
â€œAn ethanol extract ofArtemisia iwayomogi activates PPARdelta
leading to activation of fatty acid oxidation in skeletal muscle,â€
PloS ONE, vol. 7, no. 3, Article ID e33815, 2012.
[19] J. Folch, M. Folch, and G. H. Sloane Stanley, â€œA simple method
for the isolation and puriï¿½cation of total lipides from animal
tissues,â€î‚»e Journal of Biological Chemistry, vol. 226, no. 1, pp.
497â€“509, 1957.
[20] M. Mapfei, J. Halaas, E. Ravussin et al., â€œLeptin levels in human
and rodent:measurement of plasma leptin and obRNA in obese
and weight-reduced subjects,â€ Nature Medicine, vol. 1, no. 11,
pp. 1155â€“1161, 1995.
[21] G. Wang, X. Liu, K. K. Christoï¬€el et al., â€œPrediabetes is
not all about obesity: association between plasma leptin and
prediabetes in lean rural Chinese adults,â€ European Journal of
Endocrinology, vol. 163, no. 2, pp. 243â€“249, 2010.
[22] N. Kubota, Y. Terauchi, H. Miki et al., â€œPPARğ›¾ğ›¾ mediates high-
fat diet-induced adipocyte hypertrophy and insulin resistance,â€
Molecular Cell, vol. 4, no. 4, pp. 597â€“609, 1999.
[23] A. V. Hertzel and D. A. Bernlohr, â€œRegulation of adipocyte
gene expression by polyunsaturated fatty acids,â€Molecular and
Cellular Biochemistry, vol. 188, no. 1-2, pp. 33â€“39, 1998.
[24] P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B.
M. Spiegelman, â€œmPPARğ›¾ğ›¾2: tissue-speciï¿½c regulator of an
adipocyte enhancer,â€ Genes and Development, vol. 8, no. 10, pp.
1224â€“1234, 1994.
[25] P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. î¢omazy, and R.
M. Evans, â€œPPARğ›¾ğ›¾ promotes monocyte/macrophage diï¬€eren-
tiation and uptake of oxidized LDL,â€ Cell, vol. 93, no. 2, pp.
241â€“252, 1998.
[26] J. Phan, M. PÃ©terfy, and K. Reue, â€œLipin expression preceding
peroxisome proliferator-activated receptor-ğ›¾ğ›¾ is critical for adi-
pogenesis in vivo and in vitro,â€ Journal of Biological Chemistry,
vol. 279, no. 28, pp. 29558â€“29564, 2004.
[27] H. S. Sul and D. Wang, â€œNutritional and hormonal regulation
of enzymes in fat synthesis: studies of fatty acid synthase
and mitochondrial glycerol-3-phosphate acyltransferase gene
transcription,â€Annual Review of Nutrition, vol. 18, pp. 331â€“351,
1998.
[28] C. T. Coburn, F. F. Knapp Jr., M. Febbraio, A. L. Beets, R.
L. Silverstein, and N. A. Abumrad, â€œDefective uptake and uti-
lization of long chain fatty acids in muscle and adipose tissues
of CD36 knockout mice,â€ Journal of Biological Chemistry, vol.
275, no. 42, pp. 32523â€“32529, 2000.
[29] I. Tzameli, H. Fang, M. Ollero et al., â€œRegulated produc-
tion of a peroxisome proliferator-activated receptor-ğ›¾ğ›¾ ligand
during an early phase of adipocyte diï¬€erentiation in 3T3-L1
adipocytes,â€ Journal of Biological Chemistry, vol. 279, no. 34, pp.
36093â€“36102, 2004.
[30] G. Boden, â€œObesity and free fatty acids,â€ Endocrinology and
MetabolismClinics of North America, vol. 37, no. 3, pp. 635â€“646,
2008.
[31] H. Ruan, N. Hacohen, T. R. Golub, L. Van Parijs, and H.
F. Lodish, â€œTumor necrosis factor-ğ›¼ğ›¼ suppresses adipocyte-
speciï¿½c genes and activates expression of preadipocyte genes
in 3T3-L1 adipocytes: nuclear factor-ğœ…ğœ…B activation by TNF-ğ›¼ğ›¼
is obligatory,â€ Diabetes, vol. 51, no. 5, pp. 1319â€“1336, 2002.
[32] T. Suganami, J. Nishida, and Y. Ogawa, â€œA paracrine loop
between adipocytes and macrophages aggravates inï¿½ammatory
changes: role of free fatty acids and tumor necrosis factor ğ›¼ğ›¼,â€
Arteriosclerosis, î‚»rombosis, and Vascular Biology, vol. 25, no.
10, pp. 2062â€“2068, 2005.
[33] J. V. Castell, M. J. Gomez-Lechon, M. David, R. Fabra, R. Trul-
lenque, and P. C. Heinrich, â€œAcute-phase response of human
hepatocytes: regulation of acute-phase protein synthesis by
interleukin-6,â€ Hepatology, vol. 12, no. 5, pp. 1179â€“1186, 1990.
[34] S. A. Burstein, J. Peng, P. Friese et al., â€œCytokine-induced
alteration of platelet and hemostatic function,â€ Stem Cells, vol.
14, no. 1, pp. 154â€“162, 1996.
[35] H. Kanda, S. Tateya, Y. Tamori et al., â€œMCP-1 contributes to
macrophage inï¿½ltration into adipose tissue, insulin resistance,
and hepatic steatosis in obesity,â€ Journal of Clinical Investigation,
vol. 116, no. 6, pp. 1494â€“1505, 2006.
[36] T. Sareneva, S. Matikainen, M. Kurimoto, and I. Julkunen,
â€œInï¿½uenza A virus-induced IFN-ğ›¼ğ›¼/ğ›½ğ›½ and IL-18 synergistically
enhance IFN-ğ›¾ğ›¾ gene expression in human T cells,â€ Journal of
Immunology, vol. 160, no. 12, pp. 6032â€“6038, 1998.
[37] D. E. Moller, â€œPotential role of TNF-ğ›¼ğ›¼ in the pathogenesis of
insulin resistance and type 2 diabetes,â€ Trends in Endocrinology
and Metabolism, vol. 11, no. 6, pp. 212â€“217, 2000.
[38] P. J. Klover, T. A. Zimmers, L. G. Koniaris, and R. A. Mooney,
â€œChronic exposure to interleukin-6 causes hepatic insulin
resistance in mice,â€ Diabetes, vol. 52, no. 11, pp. 2784â€“2789,
2003.
[39] N. Kamei, K. Tobe, R. Suzuki et al., â€œOverexpression of
monocyte chemoattractant protein-1 in adipose tissues causes
macrophage recruitment and insulin resistance,â€ Journal of
Biological Chemistry, vol. 281, no. 36, pp. 26602â€“26614, 2006.
[40] R. Feinstein, H. Kanety, M. Z. Papa, B. Lunenfeld, and A.
Karasik, â€œTumor necrosis factor-ğ›¼ğ›¼ suppresses insulin-induced
tyrosine phosphorylation of insulin receptor and its sub-
strates,â€ Journal of Biological Chemistry, vol. 268, no. 35, pp.
26055â€“26058, 1993.
[41] B. Cohen,D.Novick, andM.Rubinstein, â€œModulation of insulin
activities by leptin,â€ Science, vol. 274, no. 5290, pp. 1185â€“1188,
1996.
[42] Z. Zhao, Y.Hu, Z. Liang, J. P. S. Yuen, Z. Jiang, andK. S. Y. Leung,
â€œAuthentication is fundamental for standardization of Chinese
medicines,â€ Planta Medica, vol. 72, no. 10, pp. 865â€“874, 2006.
[43] A. R. Kim, Y. N. Zou, T. H. Park et al., â€œActive components from
Artemisia iwayomogi displaying ONOO-scavenging activity,â€
Phytotherapy Research, vol. 18, no. 1, pp. 1â€“7, 2004.
[44] H. H. Yu, Y. H. Kim, B. S. Kil, K. J. Kim, S. I. Jeong, and Y.
O. You, â€œChemical composition and antibacterial activity of
essential oil ofArtemisia iwayomogi,â€ PlantaMedica, vol. 69, no.
12, pp. 1159â€“1162, 2003.
[45] Y. Ding, C. Liang, S. Y. Yang et al., â€œPhenolic compounds from
Artemisia iwayomogi and their eï¬€ects on osteoblastic MC3T3-
E1 cells,â€ Biological and Pharmaceutical Bulletin, vol. 33, no. 8,
pp. 1448â€“1453, 2010.
[46] J. M. Han, H. G. Kim, M. K. Choi et al., â€œAqueous extract
of Artemisia iwayomogi Kitamura attenuates cholestatic liver
ï¿½brosis in a rat model of bile duct ligation,â€ Food and Chemical
Toxicology, vol. 50, no. 10, pp. 3505â€“3513, 2012.
Evidence-Based Complementary and Alternative Medicine 11
[47] J. H. Wang, M. K. Choi, J. W. Shin, S. Y. Hwang, and C. G.
Son, â€œAntiï¿½brotic eï¬€ects of Artemisia capillaris and Artemisia
iwayomogi in a carbon tetrachloride-induced chronic hepatic
ï¿½brosis animal model,â€ Journal of Ethnopharmacology, vol. 140,
no. 1, pp. 179â€“185, 2012.
[48] E. Shin, K. M. Choi, H. S. Yoo, C. K. Lee, B. Y. Hwang, and M.
K. Lee, â€œInhibitory eï¬€ects of coumarins from the stem barks of
fraxinus rhynchophylla on adipocyte diï¬€erentiation in 3T3-L1
cells,â€ Biological and Pharmaceutical Bulletin, vol. 33, no. 9, pp.
1610â€“1614, 2010.
[49] J. T. Hwang, S. H. Kim, H. J. Hur et al., â€œDecursin, an active
compound isolated from Angelica gigas, inhibits fat accumu-
lation, reduces adipocytokine secretion and improves glucose
tolerance inmice fed a high-fat diet,â€PhytotherapyResearch, vol.
26, no. 5, pp. 633â€“638, 2012.
[50] S. K. Dharmarajan and K. M. Arumugam, â€œComparative eval-
uation of ï¿½avone from Mucuna pruriens and coumarin from
Ionidium suï¬€ruticosum for hypolipidemic activity in rats fed
with high Fat diet,â€ Lipids in Health and Disease, vol. 11, article
126, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinsonâ€™s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
